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Abstract
Background—Some studies suggest that maternal influenza vaccination can improve birth 
outcomes. However, there are limited data from tropical settings, particularly Southeast Asia. We 
conducted an observational study in Laos to assess the effect of influenza vaccination in pregnant 
women on birth outcomes.
Methods—We consented and enrolled a cohort of pregnant woman who delivered babies at 3 
hospitals during April 2014–February 2015. We collected demographic and clinical information 
on mother and child. Influenza vaccination status was ascertained by vaccine card. Primary 
outcomes were the proportion of live births born small for gestational age (SGA) or preterm and 
mean birth weight. Multivariate models controlled for differences between vaccinated and 
unvaccinated women and influenza virus circulation.
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Results—We enrolled 5103 women (2172 [43%] were vaccinated). Among the 4854 who had a 
live birth, vaccinated women were statistically significantly less likely than unvaccinated women 
to have an infant born preterm during the period of high influenza virus circulation (risk ratio [RR] 
= 0.56, 95% confidence interval [CI], .45–.70), and the effect remained after adjusting for 
covariates (adjusted RR, 0.69; 95% CI, .55–.87). There was no effect of vaccine on SGA or mean 
birth weight. The population-prevented fraction was 18.0%.
Conclusions—In this observational study, we found indirect evidence of influenza vaccine 
safety during pregnancy, and women who received vaccine had a reduced risk of delivering a 
preterm infant during times of high influenza virus circulation. Vaccination may prevent 1 in 5 
preterm births that occur during periods of high influenza circulation.
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Influenza virus infections in pregnant women are associated with higher risks of severe 
outcomes, both during pandemics and seasonal influenza years [1–3]. Influenza vaccines are 
safe for pregnant women and their fetuses [4–7] and are effective in reducing the incidence 
of influenza among pregnant women [8, 9]. In addition, vaccination of pregnant women has 
reduced the risk of influenza in their infants during the first 6 months of life, a time of very 
high risk of severe influenza disease [8, 10]. In 2012, the World Health Organization (WHO) 
Strategic Advisory Group of Experts recommended that any country with an influenza 
immunization program should vaccinate pregnant women as a first priority [11]. National 
vaccination programs that target pregnant women have increased in some parts of the world 
[12]. In Southeast Asia, few countries recommend influenza vaccine in pregnant women 
[13].
In addition to the direct effect in preventing influenza illness, there is great interest in 
whether seasonal influenza vaccines could have an indirect effect on birth outcomes. 
Influenza virus infection during pregnancy is associated with an increased frequency of 
preterm birth and neonatal death [14]. Some observational studies have demonstrated a 
protective effect of influenza vaccination on adverse birth outcomes [15, 16], while others 
have shown no effect [17] and 2 randomized controlled trials showed different effects [8, 
18]. Given the global mortality burden and cost associated with infants who have poor birth 
outcomes [19, 20], there are important implications of a protective vaccine effect. Moreover, 
the impact may vary by population or geographic-specific factor such as influenza 
seasonality and baseline rates of low-birth-weight or preterm births. Therefore, there is a 
need to evaluate possible associations in a variety of settings.
Since 2012, Lao People’s Democratic Republic (Laos) has offered influenza vaccine free of 
charge to high-risk persons, including pregnant women [21]. Laos is a country with a lower–
middle income economy, with high rates of poor birth outcomes that have improved little in 
the last decade (S. Olsen, unpublished data). In 2014–2015, we conducted an observational 
study in pregnant women to assess the effect of influenza vaccine on birth outcomes.
Olsen et al. Page 2














Study Design and Population
In this observational study, we enrolled a cohort of pregnant women at the time of delivery 
or miscarriage at 3 hospitals in Laos (the Mother and Child Health [MCH] and Setthathirath 
hospitals in Vientiane Capital Province and Luang Prabang Hospital in Luang Prabang 
Province). Laos is a Southeast Asian country with a population of 6.8 million and an annual 
birth cohort of 179 042 [22]. The objectives were to compare the proportion of infants born 
small for gestational age (SGA) or preterm and the mean birth weight among infants born to 
women who received and those who did not receive influenza vaccine from 20 March 2014 
through 30 June 2014 and who delivered between April 2014 and February 2015.
Study Enrollment
From April 2014 through February 2015, we enrolled pregnant women who were aged ≥18 
years, delivered at 1 of the 3 designated hospitals, were a resident of Vientiane Capital 
Province or Luang Prabang Province for at least the last 30 days, and had a singleton birth. 
Each woman provided written informed consent. A healthcare provider administered a brief 
questionnaire in the local language, usually within 12 hours of delivery. We collected the 
following information: demographic, pregnancy history, household income, underlying 
health conditions, respiratory illness during pregnancy, influenza vaccination status and date 
(self-report and documented), and birth outcomes. Medical records and vaccine registries are 
not regularly maintained at Laotian healthcare facilities; however, pregnant women are 
provided an antenatal care (ANC) booklet to record ANC visit information and are advised 
to bring this booklet to all ANC visits and their delivery. Information was obtained from the 
ANC booklets, interviews, and vaccination cards (see below).
Vaccine and Exposure Definition
The seasonal influenza vaccination campaign was conducted from 20 March 2014 through 
30 June 2014 (see Supplementary Materials). The vaccine used was Afluria, the 2013–2014 
Northern Hemisphere formulation of the trivalent inactivated influenza vaccine [23], donated 
by bioCSL Biotherapies Inc. (Australia). At the time of vaccination, each pregnant woman 
received 1 dose and was given a vaccination card documenting the date of vaccination. The 
woman brought this card to the healthcare facility at the time of delivery. We defined 
vaccination as documented receipt of vaccine at least 14 days before delivery. We also 
calculated a variable for weeks of protection (see Supplementary Materials).
Primary Outcomes
Gestational age was calculated by last menstrual period captured at the first ANC visit 
(mean, week 14). SGA was calculated using the Kramer method [24], defined as a live birth 
with a birth weight less than the 10th percentile of birth weights of the same sex and same 
gestational age in weeks and expressed as a percentage of live births with gestational ages 
from 22 to 43 weeks. Preterm birth was defined as gestational age <37 weeks. Infant birth 
weight was measured at delivery.
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We used sentinel surveillance data for influenza-like illness to define periods of influenza 
activity [25]. We plotted weekly positivity and a 3-week moving average. We designated 
months as high (≥15% samples positive on real-time reserve transcription polymerase chain 
reaction assay) and low (<15%) influenza activity (Figure 1). Using this threshold, the 
continuous period of April 2014 to July 2014 experienced low influenza activity and August 
2014 to February 2015 experienced high influenza activity. May 2014 (weeks 19–22) was a 
month with high activity (17%) but was kept in the “low influenza activity” period for the 
primary analysis. We used the period of low influenza activity as a control period during 
which we would expect little or no effect of vaccination.
Sample Size
Assuming a type I error of 5%, a type 2 error of 20%, and an influenza vaccine coverage in 
pregnant women of 50%, we estimated we would need to enroll 614 pregnant women to 
detect a difference of 9 percentage points in SGA (24% in unvaccinated vs 15% vaccinated, 
as estimated from Lee et al [19]) and 1100 pregnant women to detect a difference of 70 g in 
mean birth weight using a standard deviation of 390 (a difference estimated from 
unpublished 2013 data in vaccinated and unvaccinated women at MCH Hospital). In a post 
hoc sample size calculation for preterm birth, we estimated we would need 1937 pregnant 
women to detect a difference of 4 percentage points (12% in unvaccinated and 8% in 
vaccinated).
Statistical Analyses and Confounder Assessment
Data were double entered into Access (Microsoft Office 2010) and imported into SPSS 
(IBM SPSS Statistics, version 21) and Stata (StataCorp, release 12) for analysis. We 
compared characteristics of women vaccinated (with documentation) and unvaccinated using 
χ2 test or analysis of variance for categorical variables and t test for continuous variables; P 
< .05 was considered statistically significant.
We conducted bivariate analysis in order to compare birth outcomes by maternal vaccination 
status among all live births stratified by influenza activity (high/low). A priori we considered 
influenza activity and province as possible effect modifiers and used regression (log 
binomial for SGA and preterm birth [dichotomous] and linear for mean birth weight 
[continuous]) to assess for interaction between each variable and vaccination using the Wald 
χ2 test. For the multivariate analysis, we built log binomial models to evaluate the risk ratio 
(RR) of each dichotomous birth outcome (SGA status and preterm birth) and a multivariate 
linear regression model to predict the change in value of mean birth weight by vaccination 
status. We included covariates in each model that were statistically significant at P < .05 on 
bivariate analysis or otherwise considered in the existing literature as associated with both 
vaccination status and birth outcomes [15, 26, 27]. We report results for the full model. We 
also stratified by influenza activity (high/low) and ran the model after dropping this term 
from the model; results are also presented for each stratum. We then ran the model using 
weeks of protection instead of vaccinated (yes/no) but dropped the term “influenza activity” 
since it correlated with weeks of protection. We report adjusted risk ratios (aRRs) and 95% 
confidence intervals (CIs) and the difference of means. We calculated the population 
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prevented fraction of preterm birth as shown elsewhere [15, 28]. In a separate analysis, to 
control for residual confounding, we calculated propensity scores to adjust each pregnant 
woman’s probability of being vaccinated; we also ran sensitivity analyses (see 
Supplementary Materials).
Ethics
The Ministry of Health (MoH) Institutional Ethics Review Board was not involved since the 
Department of Hygiene and Health Promotion, Maternal and Child Health Center, MoH, 
deemed that this activity did not meet study criteria. At the Centers for Disease Control and 
Prevention, the protocol was reviewed and determined to be public health evaluation, not 
research. Reporting conforms to the STROBE (strengthening the reporting of observational 
studies in epidemiology) statement [29].
RESULTS
Between 4 April 2014 and 27 February 2015, we enrolled 6668 women; 5103 were in the 
final dataset (Figure 2; Supplementary Materials). Of the 5103 women with verified 
vaccination status, 2172 (43%) were vaccinated, and coverage did not differ between 
mothers with infants born in periods with high vs low influenza activity (P = .63). Fifty-four 
percent received vaccine during the second trimester (Table 1). Of the 5103 women, 4854 
(95.1%) had a live birth, 222 (4.4%) had fetal mortality (31 miscarriages <22 weeks, 46 still 
births ≥22 weeks, 145 unknown gestational age), 14 were born live but died within 7 days 
after birth (11 died the same day as birth; 3 died 1, 4, and 6 days after birth), and 13 were 
missing an outcome. Twenty-six (11%) of the 236 deaths occurred among babies whose 
mothers were vaccinated.
Vaccinated and unvaccinated women were similar with respect to mean age (27 vs 27 years), 
mean number of people in the household (4.9 vs 5.1), frequency of having chronic disease 
(1.8% vs 1.9%), the presence of a smoker in the household (32.2% vs 33.8%), having a 
respiratory illness (8.3% vs 8.1%), or being hospitalized (0.6% vs 1.0%) during pregnancy 
(Table 1). Vaccinated women were statistically significantly more likely than unvaccinated 
women to belong to the Lao Loum ethnic group (91.2% vs 83.9%; P < .001), to have 
completed secondary school (62.9% vs 50.7%; P < .001), and to have fewer persons aged 
<15 years in the household (mean 1.6 vs 1.8; P < .001). Vaccinated women were also more 
likely to live closer to a hospital, report a higher monthly household income, and have had 4 
or more ANC visits (94.7% vs 68.7%; P < .001).
To assess the effect of vaccination on birth outcomes, we limited the analytic dataset to live 
births (n = 4854). The proportion classified as SGA was 4.2%, and this did not differ for 
infants born to vaccination and unvaccinated mothers (4.7% vs 3.8%; P = .16; Table 2). 
There was no difference in the crude or adjusted risk of SGA among vaccinated women, and 
the same was true when the data were stratified by high or low influenza activity (Table 2). 
The proportion of live births classified as preterm was 10.2%, and this differed significantly 
by vaccinated and unvaccinated mothers (7.5% vs 12.8%; P < .001). The crude (RR = 0.58; 
95% CI, .48–.71) and (aRR = 0.70; 95% CI, .57–.87) to vaccinated women was significantly 
protective against having an infant born preterm. When we stratified by influenza activity, 
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the protective effect of the vaccine remained only among infants born during the period of 
high influenza activity. Among live births, the mean birth weight was 3070 g, and this did 
not differ between infants born to vaccinated and unvaccinated mothers (3082 g vs 3060 g; P 
= .09). The difference in the mean birth weight after adjusting for covariates was 2 g greater 
among infants born to vaccinated women, and the means for infants born to vaccinated and 
unvaccinated had overlapping CIs; there was no difference when the data were stratified by 
influenza activity. Using weeks of protection, the only statistically significant effect was for 
preterm birth; for every week of protection there was a 4% reduced risk of preterm birth (RR 
= 0.96; 95% CI, .95–.98).
The numbers were too small to analyze the effect of trimester of maternal vaccination on 
birth outcomes. In our prespecified subgroup analysis, we found no significant interaction 
between vaccination and influenza activity for SGA (P = .77), preterm birth (P = .36), or 
birth weight (P = .31). We found no significant interaction between vaccination and province 
on SGA (P = .22) but we did find it for preterm birth (P = .01) and birth weight (P = .03). 
We estimated that the fraction of preterm births prevented in the population by vaccination 
was 8.1% in the period of low and 18.0% in the high influenza virus circulation period.
A few other variables had an independent effect on the primary outcomes (Supplementary 
Table 1A–C). Using propensity scores, the primary results for preterm birth were similar 
(see Supplementary Table 1B). In the sensitivity analysis we found no substantial differences 
(Supplementary Tables 2 and 3).
DISCUSSION
In this cohort study in Laos, we found that pregnant women who received an influenza 
vaccine were statistically significantly less likely to have an infant born preterm (ie, at <37 
weeks) compared with unvaccinated pregnant women. The effect, about a 30% reduced risk, 
was observed for the entire period, but when we stratified by influenza activity, the effect 
remained only for infants born during times of high influenza virus circulation. This 
translated to about 20% population prevented fraction in the period of high influenza 
activity, or roughly 1 in 5 preterm births being prevented by influenza vaccination. When 
weeks of protection was used as the main exposure, there was a 4% reduction in preterm 
births for every week of protection. We found no difference of effect in the 2 other birth 
outcomes. These findings provide additional indirect evidence of the safety of influenza 
vaccines during pregnancy (ie, no heightened risk of adverse birth outcomes related to 
vaccinees) but they also suggest that influenza vaccine may have a protective effect on 
preterm birth.
There is biologic plausibility that influenza virus infection could result in preterm birth—
infections lead to inflammation, a recognized mechanism for preterm birth [30, 31]—so it is 
also plausible that influenza vaccination could prevent preterm birth. In a recent review of 
studies that looked at the association between influenza vaccination and preterm birth, Fell 
and colleagues concluded that overall there appeared to be a small reduction or no difference 
in risk [17]. However, only 6 studies looked at trivalent vaccines (13 included monovalent 
pandemic vaccines) and only 2 [15, 18] of the 6 took influenza virus activity into account in 
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the analysis. Our study, which had simultaneous monitoring of influenza virus circulation, a 
large sample size, and verification of vaccination status, is an important addition to the 
literature.
The lack of an effect of vaccine on SGA was not entirely surprising for 2 reasons. First, we 
calculated an unexpectedly low frequency (4%) of SGA in our population and may not have 
had the power to detect a difference. Second, a single insult during pregnancy, such as 
influenza virus infection, may not be enough to have a sustained impact on the intrauterine 
environment and result in an infant born SGA. Moreover, the baseline birth weight in our 
population was substantially higher than in the other populations where an impact on SGA 
and birth weight was documented [18].
In many countries in Southeast Asia influenza viruses circulate year-round, so it was perhaps 
not surprising that in our study the effect of vaccination on preterm birth in the low season 
was also protective, but the difference was not statistically significant in part possibly 
because of fewer births. In fact, a higher magnitude (and significance) of association 
between maternal influenza vaccination and preterm birth during the period of high 
influenza activity supports the internal validity of our findings. There is growing recognition 
that year-round vaccination strategies may prevent more disease, particularly among 
pregnant women and their infants, and our data suggest that such a strategy may be 
beneficial in tropical settings [32].
Many factors affect birth outcomes, so it was not surprising to find that parity, education, 
ANC, and income had some independent effects. Women in this cohort had good access to 
ANC (80% had the WHO recommended more than 4 visits), and many women were 
vaccinated at an antenatal visit as this was an outreach method used during the vaccination 
campaign. Therefore, ANC and vaccination status may have some overlapping or synergistic 
effects. The observed differences in effects by province may be explained by the use of a 
Ministry of Health Maternal Neonatal Child Health package designed to increase access to 
and use of healthcare among rural and underserved communities in the Northern provinces, 
including Luang Prabang, through the provision of free care and treatment, transportation, 
and food.
This evaluation has several limitations inherent to observational studies, namely, that there 
might be unmeasured differences between people who do and do not get vaccinated [33]. 
Although we measured and controlled for differences in health-seeking behaviors and 
socioeconomic status, there may be residual confounding. Furthermore, we measured 
nonspecific effects of vaccination and, although we were able to look at the effect by the 
amount of influenza virus circulating, we do not know which pregnant women got influenza 
disease nor do we have an estimate of vaccine effectiveness in this setting; in the United 
States the vaccine effectiveness of the 2013–2014 Northern Hemisphere vaccine was about 
60% [34]. Finally, consistent with a seasonal vaccine campaign, the majority of women in 
our study were vaccinated just before the period of high influenza circulation, resulting in 
the majority delivering during this period and leaving only a small sample to evaluate 
vaccine effects in the low season.
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Influenza vaccine is safe and effective in pregnant women and should be given as 
recommended [11]. Although many factors contribute to improved outcomes for infants, our 
findings provide evidence that influenza vaccine may reduce some fraction of preterm births, 
especially in settings where the burden of preterm births is high, and further evidence that 
maternal immunization with influenza vaccine is safe. Preterm birth is a leading cause of 
infant mortality [20], and preventing even a small fraction would be an important 
achievement. Many low- and middle-income countries have high rates of poor birth 
outcomes; in tropical regions, these countries may experience year-round influenza virus 
circulation. Adding influenza vaccine to the current package of antenatal services may be 
beneficial in countries such as Laos.
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Influenza activity measured as percent positive for an influenza virus from sentinel 
surveillance for influenza-like illness [25], categorized by low and high activity, in Lao 
People’s Democratic Republic, and number of women vaccinated by week, 2014–2015.
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Enrollment of pregnant women in Lao, People’s Democratic Republic, 4 April 2014–27 
February 2015.
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Table 1
Demographic Characteristics of Women Delivering by Seasonal Influenza Vaccination Status, Lao, People’s 
Democratic Republic, 2014–2015
Characteristic of Mother Total (n = 5103), N 
(%)
Vaccinated (n = 2172), 
N (%)
Unvaccinated (n = 2931), 
N (%)
P Value
Mean age, y (range) 27 (17–49) 27 (17–44) 27 (17–49) .60
Hospital <.001
  Mother and Child Health 2218 (43.5) 934 (43.0) 1283 (43.8)
  Setthathirath 1354 (26.5) 523 (24.1) 831 (28.4)
  Luang Prabang 1531 (30.0) 715 (32.9) 816 (27.8)
Ethnic groupa <.001
  Lao Loum 4433 (86.9) 1979 (91.2) 2454 (83.8)
  Hmong 419 (8.2) 129 (5.9) 290 (9.9)
  Khamu 237 (4.6) 57 (2.6) 180 (6.1)
  Other 10 (0.2) 6 (0.3) 4 (0.1)
Educationa <.001
  None 151 (3.0) 22 (1.0) 129 (4.4)
  Some primary 276 (5.4) 70 (3.2) 206 (7.1)
  Completed primary 618 (12.2) 223 (10.3) 395 (13.5)
  Some secondary 1197 (23.5) 489 (22.6) 708 (24.3)
  Completed secondary 2844 (55.9) 1363 (62.9) 1481 (50.7)
Mean no. people in household (range) 5.0 (1–20) 4.9 (1–20) 5.1 (1–20) .02
Mean no. people aged <15 y (range) 1.7 (0–10) 1.6 (0–9) 1.8 (0–10) <.001
Distance from home to hospital <.001
  0–5 km 2036 (40.0) 969 (44.7) 1067 (36.5)
  >5–10 km 1416 (27.8) 601 (27.7) 815 (27.9)
  >10 km 1637 (32.2) 599 (27.6) 1038 (35.5)
Household income, (500 000 Kip = USD$62)
  >5 000 000 603 (11.8) 298 (13.7) 305 (10.4) <.001
  1 000 001–5 000 000 3236 (63.5) 1427 (65.7) 1809 (61.8)
  500 001–1 000 000 797 (15.6) 256 (11.8) 541 (18.5)
  ≤500 000 M 464 (9.1) 191 (8.8) 273 (9.3)
No. of antenatal visits <.001
  <4 visits 1034 (20.3) 116 (5.3) 918 (31.3)
  ≥4 visits 4066 (79.7) 2054 (94.7) 2012 (68.7)
Pregnancy history
  Mean gravida/pregnancies (range) 2.3 (1–16) 2.2 (1–11) 2.4 (1–16) <.001
  Mean parity/live deliveries (range) 0.9 (0–12) 0.7 (0–5) 1.0 (0–12) <.001
  Mean no. abortion (range) 0.5 (0–8) 0.5 (0–6) 0.5 (0–8) .03
  Mean no. live birth (range) 0.8 (0–12) 0.7 (0–5) 0.9 (0–12) <.001
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Characteristic of Mother Total (n = 5103), N 
(%)
Vaccinated (n = 2172), 
N (%)
Unvaccinated (n = 2931), 
N (%)
P Value
  Mean no. stillbirths (range) 1.3 (0–5) 1.0 (1–1) 1.4 (0–5) .25
Chronic disease 96 (1.9) 39 (1.8) 57 (1.9) .70
Smoked during pregnancy 18 (0.4) 3 (0.1) 15 (0.5) .03
Smoker in the household 1690 (33.1) 699 (32.2) 991 (33.8) .22
Respiratory illness during pregnancy 417 (8.2) 180 (8.3) 237 (8.1) .80
Hospitalized during pregnancy 42 (0.8) 13 (0.6) 29 (1.0) .13
Trimester of vaccination 1842
  First (<14 wk) 449 (24)
  Second (≥14 and <27 wk) 989 (54)
  Third (≥27 wk) 404 (22)
Unknown (missing last menstrual period) 330
a
Also significant at P < .0001 for Lao Loum vs other and completed secondary school vs other.
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